Small Modular ImmunoPharmaceuticals

Small Modular ImmunoPharmaceuticals, also knows as SMIPs, is novel class of drugs, a single-chain polypeptides, therapeutic antibodies [http://www.bumc.bu.edu/www/busm/itp/PDFs/Hohlbaum1.pdf] . Being one third to half the size of corresponding monoclonal antibodies, they have similar in vivo half life and better tissue penetration properties [http://www.trubion.com/pdf/Trubion_SMIP_Drug_Design.pdf] .

References

SMIP, or small modular immunopharmaceutical, therapeutics are single chain polypeptides comprising one binding domain, one hinge domain and one effector domain designed in an effort to meet predetermined therapeutic specifications for specific diseases. SMIP therapeutics are mono-specific (they recognize and attach to single antigen targets and initiate biological activity). Trubion is working on SMIP drug candidates that target validated antigens with the same specificity and predictable biological activity as mAbs.


Wikimedia Foundation. 2010.

Look at other dictionaries:

  • Small modular immunopharmaceutical — Small modular immunopharmaceuticals (zu dt. „Kleine modulare Immunopharmazeutika“), kurz SMIPs, sind künstliche, von Antikörpern abgeleitete Proteine. Sie sind modular aufgebaut und bestehen wie Antikörper aus einer Antigen erkennenden… …   Deutsch Wikipedia

  • SMIP — could refer to:*Small Modular ImmunoPharmaceuticals *Ship Maintenance Improvement Program *Singapore Math Implementation Project *Sorghum and Millet Improvement Program (Zimbabwe) *St. Mary Immaculate Parish *Spares Management Improvement Program …   Wikipedia

  • Trubion — Trubion is a publicly held biopharmaceutical company that is focused on creating a pipeline of protein based therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. Trubion was established in 1999 in the State of …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.